Effects of Recombinant Interferon α-2b Combined with Budesonide and Ipratropium Bromide on Efficacy of Bronchiolitis and IL-18 and IL-33 in Children
DIAO Min1, ZHANG Chonglin1*, ZHAO Xiuxia2
The purpose of this study was to investigate the efficacy of recombinant human interferon α-2b combined with budesonide and ipratropium bromide in the treatment of bronchiolitis and its effects on IL-18 and IL-33 in children with bronchiolitis. Eighty-eight children with bronchiolitis treated in our hospital from January 2016 to January 2017 were randomly divided into control group (n=44) and observation group (n=44). The children in the two groups were given routine treatment such as antitussive, expectorant, antiasthmatic, anti-infective and antiviral therapy. The control group was treated with budesonide and ipratropium bromide on the basis of routine treatment. The observation group was treated with recombinant human interferon α-2b in addition to the control group. Both groups were treated for 7 days. The clinical efficacy and the recurrence rate of RSV (respiratory syncytial virus pneumonia) infection within 4 months were compared between the two groups. At the same time, the levels of serum IL-18 (interleukin-18), IL-33 (interleukin-33), TNF-α (tumor necrosis factor-α), ECP (eosinophilic cell cationic protein) and EOS (eosinophilic cells) were compared between the two groups before and after treatment. The results showed that the total effective rate of the observation group was 95.45%, which was higher than that of the control group (81.82%), and the difference was statistically significant. Before treatment, there was no significant difference in serum IL-18 and IL-33 levels between the two groups. After treatment, the levels of IL18, IL-33 and TNF-α in the observation group were significantly lower than those in the control group, and there was significant difference between the two groups. Before treatment, there was no significant difference in the levels of ECP and EOS between the two groups, but after treatment, the levels of ECP and EOS in the observation group (7.22±4.48 μg/mL) and EOS (124.25±40.49 μg/mL) were significantly lower than those in the control group (11.72±4.81 μg/mL and 177.18±50.08 μg/mL). During the 4-months follow-up, the recurrence rate of RSV in the observation group was 4.55%, which was significantly lower than that in the control group (22.73%). There was significant difference between the two groups (χ2 =6.18, P<0.01). This study shows that recombinant human interferon α-2b combined with budesonide and ipratropium bromide atomization is effective in the treatment of bronchiolitis in children, which can effectively reduce IL-18 and IL-33, and has stable anti-inflammatory effect as well as is not easy to recur, so it is worthy of clinical application.
CN
EN